Results 41 to 50 of about 15,946 (160)

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

A new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice. [PDF]

PLoS ONE, 2017
Despite the availability of an effective vaccine, hepatitis B virus (HBV) infection remains a major health problem. HBV e antigen (HBeAg)-negative strains have become prevalent.
Lei Wang, Min Cao, Qing Lu Wei, Zhong Hua Zhao, Qin Xiang, Hui Juan Wang, Hua Tang Zhang, Guo Qi Lai   +7 more
doaj   +1 more source

Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection

Vaccines, 2021
During the natural course of chronic hepatitis B virus (HBV) infection, the hepatitis B e antigen (HBeAg) is typically lost, while the direct transmission of HBeAg-negative HBV may result in fulminant hepatitis B.
Anna D. Kosinska, Julia Festag, Martin Mück-Häusl, Marvin M. Festag, Theresa Asen, Ulrike Protzer   +5 more
doaj   +1 more source

Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 420-434, March 2025.
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S. Feigelman, Francine Johansson Azeredo   +6 more
wiley   +1 more source

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

International Journal of Infectious Diseases, 2020
Background: In some previous studies, serum hepatitis B virus RNA (HBV RNA) was proposed as an HBV viral marker during therapy. However, the dynamic change of HBV RNA, the correlation of HBV RNA with cccDNA, and the combination of HBV RNA with known HBV ...
Xiaomei Wang, Zhongfeng Wang, Xiumei Chi, Ruihong Wu, Qinglong Jin, Hongqin Xu, Xiuzhu Gao, Lei Yu, Yuping Chen, Jia Shang, Longgen Liu, Shuqin Zhang, Yongfang Jiang, Mingxiang Zhang, Qiaoxia Tong, Lunli Zhang, Youwen Tan, Anlin Ma, Shuangsuo Dang, Bin Xu, Zhenjing Jin, Jia Li, Xiaobo Li, Fengmin Lu, Junqi Niu   +24 more
doaj   +1 more source

Incidence and Characteristics of HBV Reactivation‐Related Events Following HBsAg Seroclearance: Long‐Term Follow‐up of a Population‐Based Cohort in Japan

Hepatology Research, EarlyView.
In a population‐based cohort in Japan, HBV reactivation‐related events were observed after HBsAg seroclearance, including one virologically confirmed hepatic flare occurring spontaneously without chemotherapy or immunosuppression. These findings indicate that HBsAg seroclearance does not always represent complete viral eradication, supporting the need ...
Kazumi Yamasaki, Satoshi Shirahama, Takahiro Yasaka, Shota Yamaguchi, Masashi Mizokami, Junko Tanaka, Hiroaki Okamoto, Hiroshi Yatsuhashi   +7 more
wiley   +1 more source

A survey of the frequency of HBsAg+ status in pregnant women attending health centers in Ahwaz

Payesh, 2004
Objective(s): To estimate a frequency of HBsAg prevalence by a simple sampling method on 120 pregnant women attending health centers in Ahwaz city between March and December 1998.
Mohammad jaffari R, Saadati N, Vaziri Esfarjani Sh, Soorani Yan-Cheshmeh A   +3 more
doaj  

An HBV‐Derived Peptide Poly6 as a Novel Candidate for Functional Cure Via IFN‐I–Mediated Epigenetic Regulation of cccDNA

Journal of Medical Virology, Volume 98, Issue 4, April 2026.
ABSTRACT Covalently closed circular DNA (cccDNA) represents the central obstacle to achieving a functional cure for chronic hepatitis B virus (HBV) infection. Poly6, a peptide encoded within the HBV genome, was investigated for antiviral efficacy in hepatocyte‐derived cell lines, hydrodynamic injection models, and HBV transgenic mice.
Junghwa Jang, Dong Hyun Kim, Ziyun Kim, Eunseo Kim, Yu‐Min Choi, Bum‐Joon Kim   +5 more
wiley   +1 more source

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source